RAPGEF3 and atherosclerosis: Moreover, evidence is also emerging that EPAC1 is also a candidate drug target in vascular endothelial cells (VECs) due to its ability to attenuate pro-inflammatory cytokine signalling normally associated with atherosclerosis and neointimal hyperplasia (NIH), which arises from mechanical injury during angioplasty with stents [14,37].